NASDAQ:SUPN

Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

$31.80

-0.74 (-2.27%)

(As of 09/27/2022 12:00 AM ET)

Add

Compare

Today's Range: $31.44
▼
$33.15
50-Day Range: $29.51
▼
$35.51
52-Week Range: $24.95
▼
$36.08

Volume: 701,346 shs
Average Volume: 377,235 shs
Market Capitalization: $1.70 billion

P/E Ratio: 31.49
Dividend Yield: N/A
Price Target: $41.00

Supernus Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 28.9% Upside
$41.00 Price Target
Short Interest: Bearish
11.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$2.16 M Sold Last Quarter
Proj. Earnings Growth: -31.79%
From $1.51 to $1.03 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

708th out of 1,071 stocks

Pharmaceutical Preparations Industry

332nd out of 531 stocks

3.5

Analyst's Opinion

Consensus Rating
Supernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.00, Supernus Pharmaceuticals has a forecasted upside of 28.9% from its current price of $31.80.
Amount of Analyst Coverage
Supernus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.97% of the float of Supernus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Supernus Pharmaceuticals has recently increased by 8.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Supernus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Supernus Pharmaceuticals does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Supernus Pharmaceuticals has received a 58.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topiramate", "Safinamide", "Oxcarbazepine", and "Amantadine" products. See details.
Environmental Sustainability
The Environmental Impact score for Supernus Pharmaceuticals is -2.35.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Supernus Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 3 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,161,863.00 in company stock.
Percentage Held by Insiders
Only 8.70% of the stock of Supernus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
99.81% of the stock of Supernus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Supernus Pharmaceuticals are expected to decrease by -31.79% in the coming year, from $1.51 to $1.03 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Supernus Pharmaceuticals is 31.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Supernus Pharmaceuticals is 31.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 122.55.
Price to Book Value per Share Ratio
Supernus Pharmaceuticals has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

September 20, 2022 | americanbankingnews.com

Critical Contrast: Supernus Pharmaceuticals (NASDAQ:SUPN) & Celsion (NASDAQ:CLSN)

September 7, 2022 | finance.yahoo.com

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

August 31, 2022 | finance.yahoo.com

Supernus to Present at the 2022 Wells Fargo Healthcare Conference

August 31, 2022 | finance.yahoo.com

Supernus Pharmaceuticals Appears Ready for an Upside Breakout

August 13, 2022 | nasdaq.com

Is Supernus Pharmaceuticals (NASDAQ:SUPN) A Risky Investment?

August 11, 2022 | finance.yahoo.com

The past five years for Supernus Pharmaceuticals (NASDAQ:SUPN) investors has not been profitable

August 8, 2022 | finance.yahoo.com

Best Momentum Stocks to Buy for August 8th

August 7, 2022 | seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Supernus Announces Second Quarter 2022 Financial Results

August 4, 2022 | finance.yahoo.com

Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates

July 29, 2022 | seekingalpha.com

Supernus: A Work In Progress

July 25, 2022 | finance.yahoo.com

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 25, 2022 | forbes.com

Berkshire, Applied Materials And Two Other Stock Buys That Combine Growth And Value

July 5, 2022 | nasdaq.com

SUPN Makes Bullish Cross Above Critical Moving Average

June 2, 2022 | finance.yahoo.com

Supernus to Participate in the Jefferies Healthcare Conference

May 10, 2022 | seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2022 Results - Earnings Call Transcript

May 9, 2022 | seekingalpha.com

Supernus Pharmaceuticals GAAP EPS of $0.43 misses by $0.02, revenue of $152.51M beats by $2.04M

May 9, 2022 | finance.yahoo.com

Supernus Announces First Quarter 2022 Financial Results

May 6, 2022 | seekingalpha.com

Supernus Pharmaceuticals Q1 2022 Earnings Preview

May 3, 2022 | bizjournals.com

This Maryland biotech’s ADHD drug just earned FDA approval — this time, for adults

May 2, 2022 | markets.businessinsider.com

FDA Approves Supernus Pharmaceuticals' Qelbree For Treatment Of ADHD In Adults

May 2, 2022 | finance.yahoo.com

This MoCo biotech’s ADHD drug just earned FDA approval — this time, for adults

May 2, 2022 | finance.yahoo.com

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

May 2, 2022 | nasdaq.com

Supernus Pharma: FDA Approves Expanded Indication For Qelbree - Quick Facts

May 2, 2022 | seekingalpha.com

Supernus rises on FDA label expansion of ADHD therapy

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Company Calendar

Last Earnings: 8/04/2022
Today: 9/27/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:SUPN
CUSIP: 86845910
CIK: 1356576
Web: www.supernus.com
Phone: (301) 838-2500
Fax: 301-838-2501
Employees: 575
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $41.00
High Stock Price Forecast: $44.00
Low Stock Price Forecast: $38.00
Forecasted Upside/Downside: +28.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.01
Trailing P/E Ratio: 31.49
Forward P/E Ratio: 21.06
P/E Growth: N/A
Net Income: $53.42 million
Net Margins: 9.12%
Pretax Margin: 9.06%
Return on Equity: 6.98%
Return on Assets: 3.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.85
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: $579.78 million
Price / Sales: 2.93
Cash Flow: $1.92 per share
Price / Cash Flow: 16.55
Book Value: $15.43 per share
Price / Book: 2.06

Miscellaneous

Outstanding Shares: 53,490,000
Free Float: 48,841,000
Market Cap: $1.70 billion
Optionable: Optionable
Beta: 1.01

Key Executives

Mr. Jack A. Khattar (Age 61)
Founder, Pres, CEO, Sec. & Director
Comp: $1.78M

Mr. Timothy C. Dec (Age 63)
Sr. VP & CFO
Comp: $457.62k

Dr. Padmanabh P. Bhatt (Age 65)
Chief Scientific Officer & Sr. VP of Intellectual Property
Comp: $598.61k

Ms. Tami T. Martin (Age 67)
Sr. VP of Regulatory Affairs
Comp: $508.5k

Dr. Jonathan Rubin (Age 61)
Sr. VP of R&D and Chief Medical Officer
Comp: $557.7k

Mr. Kevin T. Anderson (Age 60)
Compliance Officer

Dr. Todd Horich M.B.A.
Ph.D., Sr. VP of Marketing & Market Access

Mr. Taylor Raiford
Sr. VP of Sales

Dr. Bryan A. Roecklein Ph.D.
Sr. VP of Corp. Devel.

Mr. Frank Mottola (Age 50)
Sr. VP of Quality, GMP Operations & Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SUPN Stock - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings or view top-rated stocks.
What is Supernus Pharmaceuticals' stock price forecast for 2022?: 2 brokers have issued 12 month target prices for Supernus Pharmaceuticals' shares. Their SUPN share price forecasts range from $38.00 to $44.00. On average, they predict the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts.
How have SUPN shares performed in 2022?: Supernus Pharmaceuticals' stock was trading at $29.16 at the beginning of the year. Since then, SUPN stock has increased by 9.1% and is now trading at $31.80.
View the best growth stocks for 2022 here.
When is Supernus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SUPN earnings forecast.
How were Supernus Pharmaceuticals' earnings last quarter?: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Thursday, August, 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by $0.15. The specialty pharmaceutical company had revenue of $170.10 million for the quarter, compared to the consensus estimate of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a trailing twelve-month return on equity of 6.98%. The company's quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 earnings per share.
What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?: Supernus Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $640.00 million-$680.00 million, compared to the consensus revenue estimate of $673.56 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?: 20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.
What other stocks do shareholders of Supernus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).
What is Supernus Pharmaceuticals' stock symbol?: Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
Who are Supernus Pharmaceuticals' major shareholders?: Supernus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Polaris Capital Management LLC (5.46%), Macquarie Group Ltd. (4.37%), Stephens Investment Management Group LLC (3.02%), Loomis Sayles & Co. L P (3.02%), Renaissance Technologies LLC (2.62%) and Aristotle Capital Boston LLC (2.37%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends.
How do I buy shares of Supernus Pharmaceuticals?: Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Supernus Pharmaceuticals' stock price today?: One share of SUPN stock can currently be purchased for approximately $31.80.
How much money does Supernus Pharmaceuticals make?: Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $1.70 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $1.01 on an earnings per share basis.
How many employees does Supernus Pharmaceuticals have?: The company employs 575 workers across the globe.
How can I contact Supernus Pharmaceuticals?: Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.

This page (NASDAQ:SUPN) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

Supernus Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month